Under a development and commercial supply agreement, Lantheus’ microbubble will be used in combination with Cerevast’s ocular ultrasound device to target improving blood flow in occluded retinal veins in the eye. Cerevast’s RVO Technology will combine intravenous administration of Lantheus’ microbubbles with non-invasive ultrasound delivered across the closed eyelid. By treating the underlying cause of the disease as opposed to the symptoms, this therapy has the potential to reduce or eliminate the need for chronic maintenance therapy and improve the quality of life for those patients inflicted by RVO. Cerevast’s RVO Technology is expected to enter a Phase 2B clinical trial in the second half of 2019. Cerevast has received an investigational device exemption (IDE) from the U.S. FDA, which allows its investigational ocular ultrasound device to be used in a clinical study in order to collect safety and effectiveness data. If approved, the RVO Technology could be commercialized in 2023.
/wp-content/uploads/2016/07/Cerevast-Medical-Logo-TM-400x62.png 0 0 Travis Rothlisberger /wp-content/uploads/2016/07/Cerevast-Medical-Logo-TM-400x62.png Travis Rothlisberger2019-04-02 09:13:482019-04-03 12:03:21Cerevast Medical Enters Into Strategic Collaboration With Lantheus Medical Imaging for Retinal Vein Occlusion Treatment